Shanghai Pharmaceuticals Holding Co., Ltd (SHPMF)
Chart Events
Performance Outlook
| Previous Close | 1.7750 |
| Open | 1.8400 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 1.8400 - 1.8400 |
| 52 Week Range | 1.2800 - 2.1000 |
| Volume | |
| Avg. Volume | 2,306 |
| Market Cap | 7.907B |
| Beta (5Y Monthly) | 0.25 |
| PE Ratio (TTM) | 6.09 |
| EPS (TTM) | 0.3020 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.06 (4.64%) |
| Ex-Dividend Date | Jul 20, 2022 |
| 1y Target Est | N/A |
- GlobeNewswire
aTyr Pharma Announces First Quarter 2022 Results and Provides Corporate Update
Company to present clinical data for efzofitimod (ATYR1923) in pulmonary sarcoidosis at upcoming American Thoracic Society International Conference in May. Planned registrational study of efzofitimod in pulmonary sarcoidosis on track to initiate in the third quarter of 2022. FDA granted orphan drug designation for efzofitimod for the treatment of systemic sclerosis; company to explore potential expansion of clinical program in other ILD. Ended the first quarter 2022 with $98.7 million in cash, c
- ACCESSWIRE
Love Hemp Group PLC Announces Update Regarding Trading Suspension
LONDON, UK / ACCESSWIRE / May 9, 2022 / Love Hemp Group PLC (AQSE:LIFE)(OTCQB:WRHLF), the brand-led consumer goods company focussed on CBD health and wellness solutions, wishes to provide an update on the temporary suspension of the trading in shares of Love Hemp.As previously announced, the reason for the suspension is that Peterhouse Capital Limited ("Peterhouse") has resigned as the AQSE Corporate Advisor and the Company needs to appoint a new AQSE Corporate Advisor in order that trading can
